Back
to home » Treatment News » Top Stories
 February 08, 2010
|
February 05, 2010
|
ViiV Drug Co-Pay Program Extended to Selzentry, Viracept and Rescriptor
ViiV Healthcare—an HIV-focused company established by GlaxoSmithKline (GSK) and Pfizer—announced it will continue a drug co-payment assistance program for drugs formerly sold by GSK and will extend the program to cover Selzentry (maraviroc), Viracept (nelfinavir) and Rescriptor (delavirdine), formerly sold by Pfizer. Co-pay assistance programs allow companies to reduce the out-of-pocket costs of medications for people with health insurance.
|
|
|
| February 04, 2010
|
February 03, 2010
|
New Drug Fights HIV and Many Other Viruses
Researchers found a new antiviral drug that appears to effectively target not only HIV, but also Ebola, influenza and Rift Valley fever, according to a study published online January 28 in the Proceedings of the National Academy of Sciences.
|
|
|
February 02, 2010
|
Rare, Serious Liver Disease Associated With HIV Drug Videx EC
The nucleoside analogue Videx EC (didanosine) is associated with a liver disorder called non-cirrhotic portal hypertension, according to a warning issued by the U.S. Food and Drug Administration (FDA). Though this form of liver disease can be serious, it is a rare occurrence among people living with HIV and using Videx EC and the drug’s benefits “continue to outweigh potential safety risks,” the agency said.
|
|
|
February 01, 2010
|
Scientists Crack Integrase Inhibitor Mystery
Scientists have grown a crystal version of an integrase enzyme very similar to HIV’s, which could help them better understand how integrase inhibitors such as Isentress (raltegravir) actually work and possibly help scientists design even better drugs. The research results will be published January 30 in Nature and were reported by ScienceDaily.
|
|
|
|
|
|
 |
|
